Diabetic Retinopathy Market Worth USD 10.11 Billion By 2022: Grand View Research, Inc.
Global Diabetic Retinopathy Market is expected to reach
USD 10.11 billion by 2022, according to a new study by Grand View Research Inc.
Diabetic retinopathy is considered as a serious sight threatening complication
that results due to long term diabetes.
The treatment line selection for
diabetic retinopathy depends on the severity of the condition and may require
intraocular injections, anti VEGF drugs, laser surgery or vitrectomy.
Increasing incidences of diabetes, rising geriatric population base and the
growing demand for early detection are some high impact rendering drivers of
the diabetic retinopathy market.
Furthermore, improving healthcare
infrastructure, rising demand for cost-effective and safe treatment and rising
focus of market players on emerging nations such as India and China are also
anticipated to propel market growth. Presence of supportive government
initiatives such as the Queen Elizabeth Diamond Jubilee Trust, which is taking
initiatives for increasing patient awareness levels in order to promote regular
retinal screening and early laser surgery to prevent permanent visual
impairment and Ophthalmic Society of South Africa which works towards the
improvement of reimbursement policies are anticipated to fuel the growth of the
diabetic retinopathy market over the forecast period.
Global diabetic retinopathy market, by type, 2012 - 2022
(USD Million)
Browse full research report on Diabetic
Retinopathy Market
Further key findings from the report suggest:
- Anti VEGF is identified as the most attractive sub segment of the diabetic retinopathy market, growing at a rate of over 6.0% over the forecast period owing to, the rising incidences of diabetes and high efficacy rates
- The non
proliferative diabetic retinopathy segment accounted for the largest
market share in 2014. The growing geriatric population and rising
incidences of blindness caused due to diabetes are some key factors
accounting for its large share. Furthermore, the increasing demand for
regular retinal screening for long time diabetic patients is also expected
to boost segment growth.
- The North
American diabetic retinopathy market accounted for over 35.0% of the
revenue in 2014 on account of, the presence of high diagnostic and
therapeutic rates in the U.S. The rising patient awareness levels and the
presence of favorable government initiatives encouraging regular retinal
screening is expected to drive regional market growth.
- The Asia
Pacific diabetic retinopathy market is likely to witness lucrative growth
over the forecast period due to, the presence of unmet needs in the
developing economies such as China and India. Presence of favorable
government initiatives to enhance retinal screening rates and improving
healthcare infrastructure are also expected to contribute towards rapid
market growth.
- Some key
players of the diabetic retinopathy market include Bayer Healthcare,
Novartis AG, ThromboGenics, Regeneron Pharmaceuticals Inc., Actavis Plc,
Alimera Sciences, BCN Peptides and Kowa Group
For more information:
http://www.grandviewresearch.com
Comments
Post a Comment